

Transcriptome and isoform reconstruction with long reads

Adam Ameur, PhD
NGI, Uppsala Genome Center
adam.ameur@igp.uu.se

Enabler for Life Sciences

National Genomics Infrastructure

NGI Stockholm



NGI Uppsala



NGI staff: 60 -70 FTE, including head of facility, lab research engineers, bioinformaticians, IT-experts, project coordinators.

UPPMAX/UPPNEX: Uppsala multidisciplinary center for advanced computational science, UPPNEX: UPPmax NEXt generation sequencing Cluster & Storage.

Enabler for Life Sciences

DNA sequencing at all scales



One of the most well-equipped NGS sites in Europe!


- 10 Illumina HiSeq Xten
- 17 Illumina HiSeq 2000/2500
- 3 Illumina MiSeq
- 1 Illumina NextSeq
- 2 Life Technologies Ion Torrent
- 6 Life Technologies Ion Proton
- 2 Pacific Biosciences RSII
- 2 Sanger ABI3730
- 1 Argus Whole Genome Map. Syst.
- 1 Oxford Nanopore Minlon

Enabler for Life Sciences

RNA-sequencing with short reads

Enabler for Life Sciences

RNA-seq: standard procedure




RNA-seq: the main question

What to do with this?




Enabler for Life Sciences




RNA-seq: analysis




Complicating factor: alternative splicing



RNA-seq: problem with short reads



RNA-seq: problem with short reads



Enabler for Life Sciences

RNA-sequencing

with very long reads!!!

Enabler for Life Sciences


Pacific Biosciences RS II

- Pacific Biosciences
 - Single molecule sequencing
 - Very long read lengths (up to 30 kb)
 - Rapid sequencing
 - Can detect base modifications (e.g. methylation)
 - Relatively low throughput

Pacific Biosciences RSII



PacBio – Sequencing Template



Polymerase Read

Definition:

- Sequence of nucleotides incorporated by polymerase while reading a template
- Includes adapters
- Often called “read”
- Includes adapters
- 1 molecule, 1 pol. read

Uses:

- QC of instrument run
- Benchmarking



Subread

Definition:

- Single pass of template
- Adapters removed
- 1 molecule, ≥ 1 subread

Unique data:

- Kinetic measurements
- Rich QVs

Uses:

- Applications



Read (of Insert)

Definition:

- Represents highest-quality single-sequence for an insert, regardless of number of passes
- Generalizes CCS for < 2 passes & RQ < 0.9
- 1 or more passes
- 1 molecule, 1 read

Uses:

- Library QC
- Applications

PacBio output

- PacBio throughput
~ 500Mb-1Gb/SMRT cell


~1 bacterial genome
~1 bacterial transcriptome
1 human genome = 150 SMRT cells



- PacBio read lengths: 500bp-30kb

PacBio – Current read lengths

- >10kb average read lengths! (run from April 2014)



Iso-Seq: Full length RNA-seq on PacBio!


- Single molecule sequencing
 - One read – one transcript
- Transcript in full length
 - No assembly required
- No systematic bias
 - CG-rich, AT-rich, tandem repeats

RNA-sequencing on PacBio


On average, 8
alt. isoforms per
gene in human




Candidate
space:
 5.8×10^{76}



PacBio Iso-Seq - library preparation



PacBio Iso-Seq – reads of insert




Full-Length = 5' primer seen, polyA tail seen, 3' primer seen

- Identify and remove primers and polyA/T tail
- Identify read strandedness


PacBio Iso-Seq: ROI of 1kb lib (2 cells)

Read Bases of Insert	78,108,189
Mean Read Length of Insert	1,687
Mean Number of Passes	8.0
Number of full-length non-chimeric reads	35,467
Average full-length non-chimeric read length	1,679

Read Length Of Insert



PacBio Iso-Seq: examples



GeneCards Summary for TMEM25 Gene:

TMEM25 is a protein-coding gene. Diseases associated with TMEM25 include breast cancer.

PacBio Iso-Seq: examples (from PacBio)

Tissue	Size Selection	FL Reads	Average FL Readlength	Number of Unique FL Transcripts	Number of Gene Loci	Max Transcript Length
Brain	1 - 2 kb	159792	1785	10289	6356	8823
	2 - 3 kb	165942	2794			
	3 - 6 kb	118568	4104			
	5 - 10 kb	59607	6490			
Heart	1 - 2 kb	134462	1629	6896	4352	8528
	2 - 3 kb	89472	2910			
	3 - 6 kb	126927	4027			
	5 - 10 kb	43486	6323			
Liver	1 - 2 kb	197772	1725	6124	3497	4754
	2 - 3 kb	157531	2605			
	3 - 6 kb	130438	3876			


<http://blog.pacificbiosciences.com/2014/10/data-release-whole-human-transcriptome.html>

PacBio Iso-Seq: examples (from PacBio)

Tissue	Size Selection	FL Reads	Average FL Readlength	Number of Unique FL Transcripts	Number of Gene Loci	Max Transcript Length
Brain	1 - 2 kb	159792	1785	10289	6356	8823
	2 - 3 kb	165942	2794			
	3 - 6 kb	118568	4104			
	5 - 10 kb	59607	6490			
Heart	1 - 2 kb	134462	1629	6896	4352	8528
	2 - 3 kb	89472	2910			
	3 - 6 kb	126927	4027			
	5 - 10 kb	43486	6323			
Liver	1 - 2 kb	197772	1725	6124	3497	4754
	2 - 3 kb	157531	2605			
	3 - 6 kb	130438	3876			

<http://blog.pacificbiosciences.com/2014/10/data-release-whole-human-transcriptome.html>

PacBio Iso-Seq: examples (from PacBio)




<http://blog.pacificbiosciences.com/2014/10/data-release-whole-human-transcriptome.html>

PacBio Iso-Seq: experimental design

So how many SMRT cells do I need?

Approximate scope guidance:

- **1 SMRT Cell:** targeted, gene-specific isoform characterization
- **1-8 SMRT Cells:** get a high-level overview of the transcriptome and isoforms of abundant transcripts
- **8-50 SMRT Cells:** get a detailed look at most transcripts and their isoforms
- **>50 SMRT Cells:** get a very thorough look at transcriptome with rare transcripts and rare isoforms or intermediates




! Depends strongly on transcriptome complexity of the organism being studied !

Targeted RNA-sequencing with very long reads!!!

Enabler for Life Sciences

Clinical project: Chronic Myeloid Leukemia

- BCR-ABL1 fusion protein – a CML drug target



The BCR-ABL1 fusion protein can acquire resistance mutations following drug treatment

www.cambridgemedicine.org/article/doi/10.7244/cmj-1355057881

BCR-ABL1 workflow – PacBio Sequencing

Cavelier et al. *BMC Cancer* (2015) 15:45
DOI 10.1186/s12885-015-1046-y



RESEARCH ARTICLE

Open Access

Clonal distribution of *BCR-ABL1* mutations and splice isoforms by single-molecule long-read RNA sequencing

Lucia Cavalier^{1*}, Adam Ameer^{1*}, Susana Häggqvist¹, Ida Höijer¹, Nicola Cahill¹, Ulla Olsson-Strömberg² and Monica Hermanson¹


Abstract

Background: The evolution of mutations in the *BCR-ABL1* fusion gene transcript renders CML patients resistant to tyrosine kinase inhibitor (TKI) based therapy. Thus screening for *BCR-ABL1* mutations is recommended particularly in patients experiencing poor response to treatment. Herein we describe a novel approach for the detection and surveillance of *BCR-ABL1* mutations in CML patients.

Methods: To detect mutations in the *BCR-ABL1* transcript we developed an assay based on the Pacific Biosciences (PacBio) sequencing technology, which allows for single-molecule long-read sequencing of *BCR-ABL1* fusion transcript molecules. Samples from six patients with poor response to therapy were analyzed both at diagnosis and follow-up. cDNA was generated from total RNA and a 1.6 kb fragment encompassing the *BCR-ABL1* transcript was amplified using long range PCR. To estimate the sensitivity of the assay, a serial dilution experiment was performed.

Results: Over 10,000 full-length *BCR-ABL1* sequences were obtained for all samples studied. Through the serial dilution analysis, mutations in CML patient samples could be detected down to a level of at least 1%. Notably, the assay was determined to be sufficiently sensitive even in patients harboring a low abundance of *BCR-ABL1* levels. The PacBio sequencing successfully identified all mutations seen by standard methods. Importantly, we identified several mutations that escaped detection by the clinical routine analysis. Resistance mutations were found in all but one of the patients. Due to the long reads afforded by PacBio sequencing, compound mutations present in the same molecule were readily distinguished from independent alterations arising in different molecules. Moreover, several transcript isoforms of the *BCR-ABL1* transcript were identified in two of the CML patients. Finally, our assay allowed for a quick turn around time allowing samples to be reported upon within 2 days.

Conclusions: In summary the PacBio sequencing assay can be applied to detect *BCR-ABL1* resistance mutations in both diagnostic and follow-up CML patient samples using a simple protocol applicable to routine diagnosis. The method besides its sensitivity, gives a complete view of the clonal distribution of mutations, which is of importance when making therapy decisions.




BCR-ABL1 mutations at diagnosis

PacBio sequencing generates ~10 000X coverage!


BCR

ABL1



Sample from time of diagnosis:


BCR-ABL1 mutations in follow-up sample




Mutations acquired in fusion transcript.
Might require treatment with alternative drug.

BCR-ABL1 dilution series results


- Mutations down to 1% detected!



Summary of mutations in 5 CML patients




Mutations mapped to protein structure



BCR-ABL1 - Compound mutations

P1 61m

T315I




F359C




P1 68.5m



T315I




D276G



BCR-ABL1 - Multiple isoforms in one individual!




BCR-ABL1 – Isoforms and protein structure




Future bioinformatics challenge

- How to find mutations within isoforms???






Conclusions and next steps

- Sensitive method for *BCR-ABL1* analysis!
 - Also for compound mutations and isoforms
- Method now used in clinical routine!
 - Patient samples coming to the clinic over a few months
 - Response time limit: 2 weeks




Our clinical diagnostics pipeline!

Step1. Create CCS reads



Step2. Run mutation analysis

E25K	CCAGTACGGG [G/A]AGGTGTACGA	7883	7143	0.475	8516	7669	0.474	16399	14812	0.475	positive
F359V	GAAGAAAAAC [T/G]TCATCCACAG	11646	3794	0.246	12231	3968	0.245	23877	7762	0.245	positive
L384M	TGATTTTGGC [C/A]TGAGCAGTT	12784	1679	0.117	13545	1734	0.113	26249	3413	0.115	positive
M244V	GGACATCACC [A/G]TGAAGCACAA	14209	1558	0.098	15194	1695	0.1	29403	3245	0.099	positive
T315I	TATATCATCA [C/T]TGAGTTCATG	15392	793	0.049	16291	854	0.05	31683	1647	0.049	positive
L387M	CCTGAGCAGG [T/A]TGATGACAGG	13869	321	0.024	13977	403	0.028	27846	724	0.026	positive
K247R	ATGAAGCAC [A/G]TGGGGGGGG	13901	14	0.001	14805	8	0.001	28786	22	0.001	negative
L248V	GAAGCACAG [C/G]TGGGGGGGG	13708	0	0	14823	0	0	28531	0	0	negative
G250E	AAGCTGGGG [G/A]GGCCGAGTAC	13338	2	0	14453	4	0	27783	6	0	negative
Q252H	CGGGGGCCCA [G/T]TACGGGAGG	6895	0	0	7489	2	0	14384	2	0	negative
Y253H	CGGGGGCCAG [T/C]TACGGGAGGT	6877	1	0	7439	1	0	14316	2	0	negative
Y253F	GGGGGCCAGT [A/T]JCGGGGAGGT	7146	0	0	7721	0	0	14867	0	0	negative
E255V	CAGTACGGGG [A/T]JGGTGACGAG	7932	0	0	8548	0	0	16488	0	0	negative
L273M	CGTGAAGACC [T/A]TGAAGGAGGA	15642	0	0	16694	0	0	32336	0	0	negative
D276N	CTTGAAGACC [G/A]ACACATGGA	15772	5	0	16786	9	0.001	32558	14	0	negative
D276G	TTGAAGGAGG [A/G]CCACATGGAG	15848	40	0.003	16855	37	0.002	32695	77	0.002	negative
T277P	GAAGGAGGAC [A/G]CCATGGAGT	15786	10	0.001	16815	26	0.002	32601	36	0.001	negative
T277S	GAAGGAGGAC [A/T]CCATGGAGGT	15786	1	0	16815	0	0	32601	1	0	negative
T277N	AAGGAGGACA [C/A]TCATGGAGGT	15899	2	0	16939	2	0	32838	4	0	negative



Step3. Upload to result server

Details	Sample ID	Run ID	Unsequenced (count)	Unknown (count)	E000E	M244V	Y253H	E255V	E255K	D276G	T315I	F359C	F359V	F359I	L384M	L387M	R296R	Date
[1]	R3760	pb_003_1										91.6	4.6					2015-02-17
[2]	R7394	pb_003_2										96.8	2.2			1.2		2015-02-17
[3]	R7840	pb_014_3								1.9								2015-02-17
[4]	R9171	pb_014_4										14.3		85				2015-02-17
[5]	R8486	pb_014_5																2015-02-17
[6]	R4419	pb_015_1																2015-02-17
[7]	R4765	pb_015_2																2015-02-17
[8]	R7715	pb_015_3			0.6													2015-02-17
[9]	R9452	pb_015_4										99.9						2015-02-17
[10]	R5208	pb_033_1																2015-02-17
[11]	R5616	pb_033_2								4.1								2015-02-17
[12]	R8236	pb_033_3			0.6													2015-02-17
[13]	R8333	pb_033_4																2015-02-17
[14]	R8817	pb_033_5					90.7	3.1										2015-02-17
[15]	R8885	pb_033_6			1.6													2015-02-17
[16]	R0430	pb_033_7			2.4													2015-02-17
[17]	R10990	pb_033_8																2015-02-17
[18]	R9171	pb_033_9																2015-02-17
[19]	R5934	pb_033_10										35.8						2015-02-17
[20]	R9223	pb_099_1																2015-02-17

News and future directions (1)


Sequel - New PacBio instrument with higher throughput!



7x more data per SMRT cell!

News and future directions (2)

Nanopore technology - for direct RNA sequencing?



PromethION

Enables detection of modified RNA bases??